

# Helmut Butzkueven

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9067786/helmut-butzkueven-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224  
papers

9,379  
citations

45  
h-index

92  
g-index

239  
ext. papers

11,397  
ext. citations

6.3  
avg, IF

5.45  
L-index

#	Paper	IF	Citations
224	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , <b>2011</b> , 476, 214-9	50.4	1948
223	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , <b>2013</b> , 45, 1353-60	36.3	934
222	Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. <i>Annals of Neurology</i> , <b>2011</b> , 70, 897-912	9.4	263
221	LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. <i>Nature Medicine</i> , <b>2002</b> , 8, 613-9	50.5	222
220	Brain health: time matters in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 9 Suppl 1, S5-S48	4	189
219	Defining secondary progressive multiple sclerosis. <i>Brain</i> , <b>2016</b> , 139, 2395-405	11.2	172
218	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 175-187	27.4	172
217	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , <b>2017</b> , 16, 189-199	24.1	156
216	Geographical variations in sex ratio trends over time in multiple sclerosis. <i>PLoS ONE</i> , <b>2012</b> , 7, e48078	3.7	139
215	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 1190-7	5.5	130
214	Treatment decisions in multiple sclerosis - insights from real-world observational studies. <i>Nature Reviews Neurology</i> , <b>2017</b> , 13, 105-118	15	126
213	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , <b>2015</b> , 77, 425-35	9.4	118
212	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , <b>2016</b> , 80, 89-100	9.4	117
211	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , <b>2014</b> , 82, 1204-11	6.5	113
210	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , <b>2015</b> , 138, 3287-98	11.2	107
209	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 739-46	5	104
208	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , <b>2017</b> , 16, 271-281	24.1	101

207	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , <b>2013</b> , 136, 3609-17	11.2	96
206	Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination. <i>Journal of Neuroscience</i> , <b>2008</b> , 28, 5195-206	6.6	90
205	Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. <i>JAMA Neurology</i> , <b>2015</b> , 72, 405-13	17.2	83
204	Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis. <i>American Journal of Human Genetics</i> , <b>2002</b> , 70, 1125-37	11	81
203	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122686	3.7	80
202	Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. <i>Glia</i> , <b>2006</b> , 53, 696-703	9	78
201	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , <b>2020</b> , 19, 307-316	24.1	77
200	Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 658-665	13.6	76
199	Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. <i>NeuroImage</i> , <b>2009</b> , 45, 679-86	7.9	75
198	MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve. <i>NeuroImage</i> , <b>2007</b> , 37, 1138-47	7.9	72
197	Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. <i>Glia</i> , <b>2008</b> , 56, 686-98	9	71
196	Prognosticating autoimmune encephalitis: A systematic review. <i>Journal of Autoimmunity</i> , <b>2019</b> , 96, 24-34	5.5	67
195	Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. <i>Movement Disorders</i> , <b>2007</b> , 22, 590-1	7	65
194	Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 7859-64	11.5	65
193	Microstructural abnormalities in the trigeminal nerves of patients with trigeminal neuralgia revealed by multiple diffusion metrics. <i>European Journal of Radiology</i> , <b>2013</b> , 82, 783-6	4.7	64
192	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , <b>2017</b> , 140, 2426-2443	11.2	62
191	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1133-7	5.5	57
190	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , <b>2014</b> , 76, 880-90	9.4	57

189	Observational data: Understanding the real MS world. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1642-1648	5	56
188	A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor. <i>Neurology</i> , <b>2012</b> , 79, 92-9	6.5	54
187	Vitamin D for the treatment of multiple sclerosis: a meta-analysis. <i>Journal of Neurology</i> , <b>2018</b> , 265, 2893-2905	5.9	52
186	A tract-based diffusion study of cerebral white matter in neuromyelitis optica reveals widespread pathological alterations. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1013-21	5	50
185	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> , 97, e1870-e1885	6.5	50
184	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 1511-22	5	49
183	Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. <i>Pharmacology &amp; Therapeutics</i> , <b>2010</b> , 126, 82-93	13.9	49
182	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 458-468	5.5	46
181	Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. <i>Journal of Neuroscience Research</i> , <b>2008</b> , 86, 3548-55	4.4	44
180	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1343-1349	5.5	44
179	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 196-203	5.5	43
178	Data quality evaluation for observational multiple sclerosis registries. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 647-655	5	43
177	A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis. <i>PLoS ONE</i> , <b>2010</b> , 5, e13454	3.7	43
176	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 963-973 <sup>5</sup>	5.5	42
175	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , <b>2015</b> , 2, 373-87	5.3	42
174	Nitrous oxide myelopathy in an abuser of whipped cream bulbs. <i>Journal of Clinical Neuroscience</i> , <b>2000</b> , 7, 73-5	2.2	42
173	A role for galanin in human and experimental inflammatory demyelination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 15466-71	11.5	41
172	A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 5644-54	5.6	40

171	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 660-668	5.5	39
170	Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. <i>PLoS ONE</i> , <b>2010</b> , 5, e10003	3.7	39
169	Brain plasticity in relapsing-remitting multiple sclerosis: evidence from resting-state fMRI. <i>Journal of the Neurological Sciences</i> , <b>2011</b> , 304, 127-31	3.2	38
168	Diffusion tensor imaging of the optic radiations after optic neuritis. <i>Human Brain Mapping</i> , <b>2012</b> , 33, 2047-61	5.9	37
167	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , <b>2015</b> , 2, 479-91	5.3	36
166	What speech can tell us: A systematic review of dysarthria characteristics in Multiple Sclerosis. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 1202-1209	13.6	36
165	Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis. <i>Human Genetics</i> , <b>2004</b> , 114, 573-80	6.3	35
164	The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. <i>PLoS ONE</i> , <b>2013</b> , 8, e59694	3.7	34
163	Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes. <i>PLoS ONE</i> , <b>2013</b> , 8, e83825	3.7	34
162	Diffusion tensor imaging correlates of visual impairment in multiple sclerosis and chronic optic neuritis <b>2012</b> , 53, 825-32		34
161	Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor. <i>Journal of Neuroscience Research</i> , <b>2000</b> , 59, 712-21	4.4	34
160	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1157-1162	5	34
159	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , <b>2017</b> , 89, 1050-1059	6.5	31
158	Altered topological organization of white matter structural networks in patients with neuromyelitis optica. <i>PLoS ONE</i> , <b>2012</b> , 7, e48846	3.7	31
157	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1809-1818	5	31
156	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 520-32	5	30
155	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1159-71	5	30
154	Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma. <i>Journal of Clinical Neuroscience</i> , <b>2007</b> , 14, 1126-9	2.2	30

153	What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?. <i>International Journal of Molecular Sciences</i> , <b>2012</b> , 13, 12665-709	6.3	29
152	Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. <i>PLoS ONE</i> , <b>2012</b> , 7, e38661	3.7	29
151	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. <i>CNS Drugs</i> , <b>2018</b> , 32, 1159-1171	6.7	28
150	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , <b>2012</b> , 318, 94-9	3.2	27
149	Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis. <i>Multiple Sclerosis International</i> , <b>2011</b> , 2011, 315406	1.1	27
148	The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, 305-10	5.5	27
147	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 79-90	5	27
146	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , <b>2017</b> , 81, 729-739	9.4	26
145	Cortical thinning correlates with cognitive change in multiple sclerosis but not in neuromyelitis optica. <i>European Radiology</i> , <b>2014</b> , 24, 2334-43	8	26
144	Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus. <i>Journal of Neuroimmunology</i> , <b>2009</b> , 211, 105-9	3.5	26
143	Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle?. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2066	8.4	25
142	The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127080	3.7	25
141	Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in mice. <i>PLoS ONE</i> , <b>2011</b> , 6, e19665	3.7	24
140	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 266-276	5	22
139	Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanism. <i>PLoS ONE</i> , <b>2012</b> , 7, e47379	3.7	22
138	Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e63480	3.7	22
137	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 28, 235-243	4	22
136	Cladribine versus fingolimod, natalizumab and interferon [Gamma] for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1617-1626	5	21

135	Comparative efficacy of first-line natalizumab vs IFN-βr glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , <b>2016</b> , 6, 102-115	1.7	21
134	Gait and balance deterioration over a 12-month period in multiple sclerosis patients with EDSS scores ≥3. <i>NeuroRehabilitation</i> , <b>2017</b> , 40, 277-284	2	20
133	Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis. <i>Acta Neuropathologica Communications</i> , <b>2013</b> , 1, 32	7.3	20
132	Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 5042-56	15.9	20
131	Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status. <i>PLoS Genetics</i> , <b>2016</b> , 12, e1005853	6	20
130	The MSBase registry: Informing clinical practice. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1828-1834	5	19
129	Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. <i>Acta Neuropathologica</i> , <b>2019</b> , 138, 443-456	14.3	19
128	Altered thalamic functional connectivity in multiple sclerosis. <i>European Journal of Radiology</i> , <b>2015</b> , 84, 703-8	4.7	19
127	EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE). <i>PLoS ONE</i> , <b>2013</b> , 8, e55948	3.7	19
126	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 642-652	5	18
125	Parallel changes in structural and functional measures of optic nerve myelination after optic neuritis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0121084	3.7	18
124	On the utility of data from the International HapMap Project for Australian association studies. <i>Human Genetics</i> , <b>2006</b> , 119, 220-2	6.3	18
123	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , <b>2021</b> , 96, e783-e797	6.5	18
122	Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 1756286418804760	6.6	18
121	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists. <i>Journal of Clinical Neuroscience</i> , <b>2014</b> , 21, 1847-56	2.2	17
120	Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. <i>European Radiology</i> , <b>2018</b> , 28, 96-103	8	16
119	Tremor in multiple sclerosis is associated with cerebello-thalamic pathology. <i>Journal of Neural Transmission</i> , <b>2017</b> , 124, 1509-1514	4.3	16
118	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 19, 105-108	4	15

117	A genetic basis for multiple sclerosis severity: Red herring or real?. <i>Molecular and Cellular Probes</i> , <b>2016</b> , 30, 357-365	3.3	15
116	Continuing fingolimod after development of macular edema: A case report. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2014</b> , 1, e13	9.1	15
115	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 38, 101868	4	15
114	Baseline brain activity changes in patients with clinically isolated syndrome revealed by resting-state functional MRI. <i>Acta Radiologica</i> , <b>2012</b> , 53, 1073-8	2	14
113	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , <b>2020</b> , 143, 1400-1413	11.2	13
112	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2018</b> , 75, 1407-1415	17.2	13
111	Head-to-head drug comparisons in multiple sclerosis: Urgent action needed. <i>Neurology</i> , <b>2019</b> , 93, 793-809	5	13
110	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists. <i>Journal of Clinical Neuroscience</i> , <b>2014</b> , 21, 1887-11	2.2	13
109	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists. <i>Journal of Clinical Neuroscience</i> , <b>2014</b> , 21, 1857-65	2.2	13
108	Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to disability change: a longitudinal study. <i>Health and Quality of Life Outcomes</i> , <b>2013</b> , 11, 127	3	13
107	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1346-1357	5	13
106	Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes. <i>PLoS ONE</i> , <b>2012</b> , 7, e52291	3.7	13
105	Serial Diffusion Tensor Imaging of the Optic Radiations after Acute Optic Neuritis. <i>Journal of Ophthalmology</i> , <b>2016</b> , 2016, 2764538	2	13
104	Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies. <i>British Journal of Pharmacology</i> , <b>2017</b> , 174, 1895-1907	8.6	12
103	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 537	4.1	12
102	The clinical profile of NMOSD in Australia and New Zealand. <i>Journal of Neurology</i> , <b>2020</b> , 267, 1431-1443	5.5	12
101	Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients. <i>Immunogenetics</i> , <b>2007</b> , 59, 177-86	3.2	12
100	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 24, 11-19	4	12



99	Seizures in autoimmune encephalitis: Kindling the fire. <i>Epilepsia</i> , <b>2020</b> , 61, 1033-1044	6.4	11
98	Clinical isolated syndrome: a 3-year follow-up study in China. <i>Clinical Neurology and Neurosurgery</i> , <b>2011</b> , 113, 658-60	2	11
97	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. <i>JAMA Neurology</i> , <b>2020</b> , 77, 1496-1503	17.2	11
96	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 391, 72-76	3.2	11
95	Multimodal characterization of gray matter alterations in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1308-1316	5	10
94	Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor. <i>Glia</i> , <b>2015</b> , 63, 1005-20	9	10
93	Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells. <i>Life Science Alliance</i> , <b>2020</b> , 3,	5.8	10
92	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1543-1555	5	10
91	Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 465-474	5	10
90	MSCOVID19: Using social media to achieve rapid dissemination of health information. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 45, 102338	4	9
89	The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2019</b> , 12, 1756286419859183	6.6	8
88	A new era in the treatment of multiple sclerosis. <i>Medical Journal of Australia</i> , <b>2015</b> , 203, 139-41, 141e.1	4	9
87	Acoustic Speech Analytics Are Predictive of Cerebellar Dysfunction in Multiple Sclerosis. <i>Cerebellum</i> , <b>2020</b> , 19, 691-700	4.3	8
86	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , <b>2020</b> , 143, 2742-2756	11.2	8
85	Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> ,	6.5	8
84	Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2016</b> , 2, 2055217316641704	2	8
83	Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. <i>BMJ Open</i> , <b>2020</b> , 10, e038861	3	7
82	Uveitis in Patients with Multiple Sclerosis in Clinical Trials of Fingolimod: Incidence, Prevalence, and Impact on Disease Course. <i>Ophthalmology</i> , <b>2019</b> , 126, 438-444	7.3	7

81	Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 696-705	5	7
80	Galanin in glia: expression and potential roles in the CNS. <i>Exs</i> , <b>2010</b> , 102, 61-9		6
79	Common variation in the MOG gene influences transcript splicing in humans. <i>Journal of Neuroimmunology</i> , <b>2010</b> , 229, 225-31	3.5	6
78	Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 4113-4133	8.6	6
77	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , <b>2021</b> ,	6	6
76	Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 47, 102642	4	6
75	Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction?. <i>Current Treatment Options in Neurology</i> , <b>2018</b> , 20, 18	4.4	5
74	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2015</b> , 1, 205521731560193	2.7	5.193
73	Association of plasma levels of Protein S with disease severity in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2015</b> , 1, 2055217315596532	2	5
72	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1765-1774	5	5
71	The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 1768-1784	6.4	5
70	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). <i>PLoS ONE</i> , <b>2016</b> , 11, e0144834	3.7	5
69	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri Observational Program (TOP). <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 410-419	5	5
68	Novel Functional MRI Task for Studying the Neural Correlates of Upper Limb Tremor. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 513	4.1	5
67	The role of vitamin D and P2X7R in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2019</b> , 330, 159-169	3.5	4
66	Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study. <i>Molecular Medicine</i> , <b>2018</b> , 24, 27	6.2	4
65	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 695-705	5	4
64	Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 719-728	5	4

63	Epigenome-wide association studies: current knowledge, strategies and recommendations. <i>Clinical Epigenetics</i> , <b>2021</b> , 13, 214	7.7	4
62	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.. <i>Lancet Neurology, The</i> , <b>2022</b> ,	24.1	4
61	Ceruloplasmin gene-deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolution. <i>Journal of Neuroscience Research</i> , <b>2014</b> , 92, 732-42	4.4	3
60	Neuroglial responses to CNS injury: prospects for novel therapeutics. <i>Expert Review of Neurotherapeutics</i> , <b>2004</b> , 4, 869-78	4.3	3
59	Prospects for stem cell transplantation in multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , <b>2002</b> , 9, 361-7	2.2	3
58	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 647811	4.1	3
57	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> , 97, e869-e880	6.5	3
56	Validation of a precision tremor measurement system for multiple sclerosis. <i>Journal of Neuroscience Methods</i> , <b>2019</b> , 311, 377-384	3	3
55	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 755-766	5	3
54	Prognosis in autoimmune encephalitis: Database. <i>Data in Brief</i> , <b>2018</b> , 21, 2694-2703	1.2	3
53	Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1569-1577	5	3
52	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 53, 103012	4	3
51	OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 40, 101984	4	2
50	Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). <i>JMIR Research Protocols</i> , <b>2021</b> , 10, e24969	2	2
49	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211049986	5	2
48	Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients. <i>Scientific Reports</i> , <b>2020</b> , 10, 22217	4.9	2
47	Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2020</b> , 6, 2055217320957358	2	2
46	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. <i>Neurology</i> , <b>2021</b> , 96, e214-e2276.5		2

45	Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 597858	8.4	2
44	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1838-1851	5	2
43	High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2021</b> , 14, 1756286421998915	6.6	2
42	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). <i>Therapeutic Advances in Neurological Disorders</i> , <b>2021</b> , 14, 17562864211042458	6.6	2
41	Genetic Predisposition, Humans <b>2014</b> , 341-364		1
40	Commentary on "Possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection". <i>Journal of Clinical Neuroscience</i> , <b>2013</b> , 20, 312-3	2.2	1
39	Vitamin D in the treatment of multiple sclerosis: A meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, e1.95-e1	5.5	1
38	Anti-aquaporin-4 antibody positivity in neuromyelitis optica is associated with lesion activity. <i>European Neurology</i> , <b>2013</b> , 70, 113-6	2.1	1
37	Immunosuppressive therapy is valuable in aggressive multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , <b>2000</b> , 7, 561-3; discussion 564-5	2.2	1
36	Combined peripheral nerve and central nervous system demyelination in a patient with chronic inflammatory demyelinating polyneuropathy. <i>Journal of Clinical Neuroscience</i> , <b>1999</b> , 6, 358-360	2.2	1
35	Electroclinical biomarkers of autoimmune encephalitis.. <i>Epilepsy and Behavior</i> , <b>2022</b> , 128, 108571	3.2	1
34	Lesion Volume in Relapsing Multiple Sclerosis is Associated with Perivascular Space Enlargement at the Level of the Basal Ganglia.. <i>American Journal of Neuroradiology</i> , <b>2022</b> , 43, 238-244	4.4	1
33	Early clinical markers of aggressive multiple sclerosis		1
32	Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years		1
31	002 Therapeutic lag in relapsing multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, A1.2-A1	5.5	1
30	The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211035948	5	1
29	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , <b>2021</b> , 35, 1217-1232	6.7	1
28	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 722237	4.1	1

27	Multiple Sclerosis Relapses Following Cessation of Fingolimod.. <i>Clinical Drug Investigation</i> , <b>2022</b> , 42, 3553.2	1
26	The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.. <i>Current Medical Research and Opinion</i> , <b>2022</b> , 1-26	2.5 1
25	Early imaging predictors of longer term multiple sclerosis risk and severity in acute optic neuritis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2019</b> , 5, 2055217319863122	2 0
24	A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data. <i>Journal of Visualized Experiments</i> , <b>2015</b> , e53169	1.6 0
23	Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis.. <i>Autoimmunity Reviews</i> , <b>2022</b> , 21, 103057	13.6 0
22	Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 58, 103393	4 0
21	Vitamin D status in an Australian patient population: a large retrospective case series focusing on factors associated with variations in serum 25(OH)D. <i>BMJ Open</i> , <b>2020</b> , 10, e032567	3 0
20	Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis. <i>Journal of Neuroimmunology</i> , <b>2021</b> , 353, 577508	3.5 0
19	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. <i>NeuroImage: Clinical</i> , <b>2021</b> , 32, 102802	5.3 0
18	The MSBase pregnancy, neonatal outcomes, and women's health registry. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2021</b> , 14, 17562864211009104	6.6 0
17	Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> , 97, e2020-e2031	6.5 0
16	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , <b>2021</b> , 430, 118067	3.2 0
15	Failure of alemtuzumab therapy in three patients with MOG antibody associated disease.. <i>BMC Neurology</i> , <b>2022</b> , 22, 84	3.1 0
14	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585221084577	5 0
13	Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides.. <i>Autoimmunity Reviews</i> , <b>2022</b> , 103074	13.6 0
12	The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 43, 102212	4
11	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 22, 166	4
10	JC virus conversion rates in natalizumab treated patients: the melbourne longitudinal cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, e1.15-e1	5.5

- 9 Neurodegeneration in MS and NMO: The Eye and the Blood. *Multiple Sclerosis International*, **2011**, 2011, 842797 1.1
- 8 Reply to [B] there sentinel demyelination before development of primary CNS lymphoma? *Journal of Clinical Neuroscience*, **2008**, 15, 1071-1072 2.2
- 7 Multiple Sclerosis: A Haplotype Association Study. *Novartis Foundation Symposium*, **2008**, 31-45
- 6 Quantifying the impact of upper limb tremor on the quality of life of people with multiple sclerosis: a comparison between the QUEST and MSIS-29 scales.. *Multiple Sclerosis and Related Disorders*, **2022**, 58, 103495 4
- 5 085 Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri observational program (TOP). *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, A34.2-A34 5.5
- 4 086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, A35.1-A35 5.5
- 3 Longitudinal tracking of axonal loss using diffusion magnetic resonance imaging in multiple sclerosis.. *Brain Communications*, **2022**, 4, fcac065 4.5
- 2 Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.. *Pharmacoeconomics*, **2021**, 40, 323 4.4
- 1 Comprehensive clinical, radiological, pathological and biochemical analysis required to differentiate VV1 sporadic Creutzfeldt-Jakob disease from suspected variant CJD.. *BMJ Neurology Open*, **2022**, 4, e000299 1.5